Wells Fargo
ALGS icon

Wells Fargo’s Aligos Therapeutics ALGS Stock Holding History

Wells Fargo’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$577 Sell
100
-600
-86% -$3.71K ﹤0.01% 6507
2026
Q1 		$5.2K Sell
700
-800
-53% -$6.07K ﹤0.01% 6109
2025
Q4 		$14K Sell
1,500
-1,670
-53% -$15.8K ﹤0.01% 5879
2025
Q3 		$31.1K Sell
3,170
-10,600
-77% -$96.9K ﹤0.01% 5687
2025
Q2 		$99.3K Sell
13,770
-9,260
-40% -$55.4K ﹤0.01% 5197
2025
Q1 		$190K Buy
23,030
+1,230
+6% +$27K ﹤0.01% 4744
2024
Q4 		$869K Buy
+21,800
New +$421K ﹤0.01% 3803
2024
Q2 		– Sell
-12
Closed -$292 – 6882
2024
Q1 		$292 Hold
12
– – ﹤0.01% 6409
2023
Q4 		$195 Buy
12
+4
+50% +$69 ﹤0.01% 6617
2023
Q3 		$146 Hold
8
– – ﹤0.01% 6660
2023
Q2 		$192 Buy
8
+1
+14% +$27 ﹤0.01% 6716
2023
Q1 		$154 Hold
7
– – ﹤0.01% 6841
2022
Q4 		$165 Hold
7
– – ﹤0.01% 6676
2022
Q3 		$0 Buy
7
+2
+40% +$66 ﹤0.01% 6608
2022
Q2 		$0 Sell
5
-37
-88% -$1.26K ﹤0.01% 6749
2022
Q1 		$2K Sell
42
-301
-88% -$24.1K ﹤0.01% 6642
2021
Q4 		$101K Buy
+343
New +$125K ﹤0.01% 5629
2021
Q2 		– Sell
-131
Closed -$74K – 6858
2021
Q1 		$74K Sell
131
-79
-38% -$52.6K ﹤0.01% 5619
2020
Q4 		$145K Buy
+210
New +$102K ﹤0.01% 5211

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's ALGS Position: Q2 2026 in Review

Wells Fargo reduced its Aligos Therapeutics (ALGS) stake by 86% in Q2 2026, selling an estimated $3.71K and leaving 100 shares worth $577. The position accounts for ﹤0.01% of the portfolio, ranked #6507.

Wells Fargo first reported a position in ALGS in Q4 2020 and has held it in 19 quarters since. The position peaked at $869K in Q4 2024. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Wells Fargo held 100 shares of Aligos Therapeutics worth $577 as of Q2 2026.
  • Wells Fargo sold 600 Aligos Therapeutics shares in Q2 2026, an estimated $3.71K.
  • Aligos Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6507 holding.
  • Wells Fargo first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • Wells Fargo's Aligos Therapeutics position peaked at $869K in Q4 2024.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.